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The discovery of the ferroportin-hepcidin complex has led to a critical review on
the treatment of anemia and anemia of inflammation (AI). Ferroportin, the only
known mammalian iron exporter from cells to blood, is negatively regulated by
hepcidin, a hormone peptide able to bind to ferroportin, leading to its degradation.
Therefore, new efficient therapeutic interventions acting on hepcidin and ferroportin
are imperative to manage anemia and AI. Bovine milk derivative lactoferrin (bLf), a
glycoprotein able to chelate two ferric ions per molecule, is emerging as a natural
anti-inflammatory substance able to modulate hepcidin and ferroportin synthesis
through the down-regulation of interleukin-6 (IL-6). Here, an interventional study
(ClinicalTrials.gov Identifier: NCT01221844) was conducted by orally administering
100mg of 20–30% iron-saturated bLf (corresponding to 70–84 µg of elemental
iron) twice a day. This treatment was compared with the Italian standard therapy,
consisting in the oral administration of 329.7mg of ferrous sulfate once a day
(corresponding to 105mg of elemental iron). Treatments were carried out on 29 anemic
women with minor β-thalassemia (20 pregnant and 9 non-pregnant), 149 women
with hereditary thrombophilia (HT) (70 pregnant and 79 non-pregnant) affected by
AI and 20 anemic pregnant women suffering from various pathologies. In anemic
pregnant and non-pregnant women with minor β-thalassemia, presenting undetectable
hepcidin levels, differently from ferrous sulfate management, bLf decreased IL-6 (from
25 ± 8 to 6 ± 3 pg/ml) and increased total serum iron (TSI) (from 54 ± 17 to
80 ± 9 µg/dl). BLf was also more efficient than ferrous sulfate in AI treatment in
HT pregnant and non-pregnant women by decreasing both serum IL-6 (from 89
± 8 to 58 ± 6 pg/ml) and hepcidin (from 115 ± 23 to 65 ± 10 ng/ml), thus
increasing hematological parameters, such as the number of red blood cells (RBCs),
the concentration of hemoglobin, TSI and serum ferritin. BLf was also efficient in treating
anemia in other pathological pregnancies. Taken together all the results, bLf, showing
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a greater benefit and efficacy than the standard ferrous sulfate management, can be
considered as a promising compound in treating anemia and AI through its ability to
down-regulate IL-6, thus restoring ferroportin-mediated iron export from cells to blood in
a hepcidin-dependent or independent way.
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INTRODUCTION
Iron is an essential nutrient for living cells and it is pivotal
during pregnancy, in particular for the developing fetus through
maternal iron transfer as well as in the neonate through breast-
feeding and in the childhood through diet. Iron deficiency (ID) is
considered the most important nutritional disorder in the world,
being more prevalent in pregnant women where represents a
high risk factor for maternal and infant health associated with
preterm delivery, fetal growth retardation, low birth weight, and
inferior neonatal health (1). ID is also frequent in children where
is related to decreased brain functions (2, 3). Moreover, women of
reproductive age can be affected by ID due to iron loss during the
menses. An early diagnosis and a prompt management of ID and
ID anemia (IDA) are highly recommended. ID is characterized
by the low levels of total serum iron (TSI) and serum ferritin
(sFtn). Conversely, IDA is characterized by low concentrations
of hemoglobin (Hb) and low number of red blood cells (RBCs) in
addition to TSI and sFtn low levels.
The human body contains 3–4 g of iron localized in
hemoglobin of erythrocytes (about 2.0–2.5 g), in ferritin
(Ftn) within hepatocytes and macrophages (about 0.5–1 g),
in myoglobin, and in iron-containing enzymes (about 0.5 g).
A minor iron source, deriving from an equilibrated diet,
provides about 15mg of iron per day of which only about 10%,
corresponding to 1–2mg, is absorbed due to its exceptionally
poor bio-availability. A major iron source involves the recycling
of iron from the lysis of senescent erythrocytes by macrophages
(about 20 mg/day) (4, 5).
The correct balance of iron between tissues/secretions and
blood, defined iron homeostasis, is regulated by twomain factors,
ferroportin (Fpn) and hepcidin (6, 7). Fpn is the only known
mammalian iron exporter from tissues to blood (6) down-
regulated by the pro-inflammatory interleukin (IL)-6 (8, 9).
Hepcidin, a 25 amino acids cationic peptide hormone, identified
in plasma (6) and urine (10, 11), is modulated by iron stores and
it is up-regulated by pro-inflammatory cytokines, such as IL-6,
IL-1α, and IL-1β (12–16).
Overall, iron homeostasis is highly regulated through three
different pathways: iron absorption in apical side of enterocytes,
iron storage into ferritin and iron export by Fpn (17, 18).
Fpn, besides IL-6 and the amount of intracellular iron/heme, is
regulated also by hepcidin which is able to bind to Fpn, leading
to its internalization and degradation (19). Consequently, high
hepcidin concentrations inhibit iron export from cells to blood
while low levels allow iron export through Fpn (5, 20).
Interestingly, in the recent study byWillemetz et al. (21), it has
been demonstrated, in amodel of hepcidin knockout (Hamp−/−)
murine macrophages infected by Salmonella enterica, that Fpn
down-regulation can occur also in a hepcidin-independent
manner (21).
The iron homeostasis disorders consist in the up-expression
of hepcidin and the subsequent down-regulation of Fpn leading
to anemia of inflammation (AI), a pathological condition
characterized by low hematological parameters, normal-to-
elevated sFtn, high levels of IL-6 and of other pro-inflammatory
cytokines (22). These disorders are traditionally treated with
iron supplementations. However, in papers by Paesano et al.
(4) and Rosa et al. (23) the iron homeostasis disorders have
not been defined as iron deficiency but as iron delocalization,
characterized by iron overload in tissues/secretions and iron
deficiency in blood. In a pathological condition occurring
in patients affected by β-thalassemia, one of the types of
thalassemia caused by a mutation in the β-globin gene (HBB)
on chromosome 11, hepcidin production is suppressed (5, 20).
The phenotypes of β-thalassemias include β-thalassemia major,
intermedia and minor, according to the severity of the genetic
mutation. Individuals with β-thalassemia major, characterized by
marked ineffective erythropoiesis and severe hemolysis, as well as
with β-thalassemia intermedia, characterized by widely variable
symptoms and severity ranging between the two extremes of
the major and minor forms, require frequent to occasional
RBCs transfusions to sustain life (24–26). Among β-thalassemic
(27, 28), the subjects affected by minor β-thalassemia, clinically
asymptomatic and characterized by morphological abnormalities
of erythrocytes as well as by a slight lowering of the hemoglobin
levels, show the disorders of iron homeostasis sometimes leading
to a mild anemia (24). During pregnancy, despite the progress
of therapies, maternal and fetal complications, such as risk of
abortion, thromboembolism, pre-term delivery and intrauterine
growth restriction, appear to be increased in patients with β-
thalassemia major, occurring in almost 40% of pregnancies, as
well as in patients with β-thalassemia intermedia, occurring in
20–30% of pregnancies, compared to healthy ones (25, 26).
Regarding β-thalassemia minor, the incidence of premature and
low birth weight infants was found to be comparable to the
general population. Of note, there is no specific therapy for β-
thalassemia minor subjects during pregnancy, but if the anemia
becomes more severe transfusions are sometimes necessary (25,
26).
Concerning the other pathology treated in this study, the
hereditary thrombophilia (HT), there are no data in literature on
the correlation between hepcidin levels and the establishing of AI
in HT subjects. However, higher levels of serum IL-6 compared
to healthy subjects have been described in HT pregnant women
(29). HT is a genetic predisposition to the formation of venous
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thrombus due to coagulation abnormalities (30, 31). During
pregnancy, this hypercoagulable state is exacerbated due to the
increase of factors VII, VIII, X and von Willebrand factor
activities and to marked increases in fibrinogen (32). Thrombin
generation markers such as prothrombin F1 and F2 also
increase (33). Moreover, activation of the coagulation system is
characterized by the co-participation of inflammatory response
components as IL-6, IL-8, and TNF-α (34). All these changes can
predispose to several maternal and fetal complications during
the pregnancy, including pre-eclampsia, late and recurrent
early miscarriage, placental abruption, fetal growth restriction
(FGR), and intrauterine death and stillbirth (33). For all
these reasons, in order to avoid maternal and fetal sequelae,
all HT pregnant women must undergo a proper therapeutic
management.
An important component of iron and inflammatory
homeostasis machinery is an iron binding glycoprotein, named
lactoferrin (Lf), present in human secretions, like milk, saliva,
vaginal fluid, amniotic fluid, upper airway fluid, seminal plasma,
the cervical mucus, and earwax (23). Similar to proteins of
the secretions, Lf is a multifunctional glycoprotein able to
protect mucosa from the injury of microbial attachment and
colonization as well as to exert anti-inflammatory activity
(18, 35). The bovine milk derivative lactoferrin (bLf), generally
recognized as safe (GRAS) by Food and Drug Administration
(FDA-USA), is emerging as an important natural glycoprotein
able to treat IDA and AI (4, 29, 36–38). The efficacy of bLf
treatment is related to its ability to decrease IL-6 concentration
which, in turn, modulates hepcidin and Fpn synthesis. Recent
in vitro studies showed how high levels of IL-6 down-
regulate the expression of Fpn in inflamed-macrophages
and how bLf is able to efficiently revert this effect, down-
regulating IL-6 and up-regulating Fpn (8, 9). These results
demonstrate that bLf, able to decrease IL-6 levels, exerts a
role in iron and inflammatory homeostasis and, especially, in
treating AI.
Of note, previous in vivo studies have reported non-pregnant
women affected by minor β-thalassemia to possess higher levels
of IL-6 compared with non-pregnant healthy women (38).
Conversely, pregnant women suffering of minor β-thalassemia
have been found to possess higher, but not-significant, levels
of IL-6 compared with healthy pregnancies (38). Regarding HT
pregnant and non-pregnant women, they have been described
with higher levels of IL-6 compared with healthy pregnancies
(29, 38).
Here, we present the data on the efficacy of bLf oral
administration in treating anemia in minor β-thalassemic
pregnant and non-pregnant women as well as in themanagement
of AI in pregnant and non-pregnant women affected by HT. The
bLf efficacy is also reported in pregnant women suffering from
other pathologies.
Remarkably, for the first time, we demonstrate that the
efficacy of bLf in treating anemia and AI in β-thalassemic
and HT women, respectively, can be correlated, in addition
to the decrease to the IL-6, with two potential different
molecular mechanisms: hepcidin-independent for β-thalassemic
and hepcidin-dependent for HT women.
MATERIALS AND METHODS
Study Design
To compare the efficacy of bLf treatment vs. the Italian ferrous
sulfate one, usually applied worldwide as standard treatment, in
themanagement of anemia andAI in pregnant and non-pregnant
women affected by minor β-thalassemia and HT, respectively, a
monocentric interventional clinical study has been conducted.
In addition, the efficacy of bLf oral administration was also
carried out on anemic pregnant women suffering from different
pathologies as epilepsy, insulin resistance diabetes type 2, Crohn’s
disease, hypertension and HT (twin pregnancies).
Setting
The interventional clinical study (ClinicalTrials.gov Identifier:
NCT01221844) has been conducted at Clinica Fabia Mater, via
Olevano Romano 25, Rome, Italy, a secondary-level hospital
for complicated pregnancies, in accordance with the ethical
principles of the Declaration of Helsinki and the Good Clinical
Practice. Approval was granted by the Ethics Committee of
Clinica Fabia Mater, via Olevano Romano 25, Rome, Italy (FM
MOD 26022010). All women gave written informed consent
before undergoing any study procedure. All women have been
recruited from June 2010 to October 2013. All pregnant women
were examined at the time of enrolment and every 30 days at
the scheduled visits until delivery. All women of child-bearing
age were examined at the time of enrolment and 30 days after
treatments.
Patients
A total of 90 anemic pregnant women between the 6th and 8th
week of gestation has been enrolled, thereof 20 women with
minor β-thalassemia and 70 with HT, and 20 anemic affected by
other pathologies, including epilepsy (No 9), insulin resistance
diabetes type 2 (No 3), Crohn’s disease (No 3), hypertension
(No 2), and HT twin pregnancies (No 3), enrolled at different
weeks of gestation.
Pregnant women with uncomplicated pregnancy were
excluded as well as if smokers or if they had anti-phospholipid
syndrome, other concomitant diseases, infections, previous
iron supplementation therapy, recent blood transfusion(s),
obesity, and allergy to milk proteins, factors that could be
considered potential modifiers of the treatments. In addition,
this interventional clinical study included 88 anemic women of
child-bearing age, thereof 9 affected by minor β-thalassemia and
79 by HT.
Non-pregnant women were excluded if smokers or if
they had other concomitant diseases, infections, previous iron
supplementation therapy, recent blood transfusion(s), obesity
and allergy to milk proteins.
All enrolled HT pregnant and non-pregnant women received
low molecular-weight heparin (0.3 U/day of Seleparina,
Italfarmaco SpA, Milano-Italy) and low dose aspirin (100mg
every 2 days of Cardioaspirin R© 100, Bayer SpA, Milano-Italy)
to prevent and reduce the risk of venous thromboembolism and
miscarriage associated to hypercoagulability (39).
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Blood Analyses
Each blood sample was harvested, aliquoted, and stored at
−80◦C in order to analyze the parameters at different times.
The anemia is defined when one of the hematological parameters
corresponded to the following values: RBCs <4,000,000/ml, Hb
<11 g/dl, TSI <30 µg/dl, and sFtn <12 ng/ml.
The diagnosis of β-thalassemia was carried out, at the
laboratory of Clinica Fabia Mater, by the analysis of the
hematological parameters including red cell morphology and
indices that revealed microcytosis (low mean corpuscular
volume, MCV), reduced content of Hb per red cell (low mean
corpuscular hemoglobin, MCH), followed by separation and
measurement of Hb fractions through electrophoresis (40).
Moreover, TSI and sFtn were assessed from venous blood.
In particular, TSI was measured using an Iron FZ assay
(Hoffmann-LaRoche, Basel, Switzerland) based on a guanidine
hydrochloride/Ferrozine reaction, while sFtn was measured
using a radioimmunoassay (Spectria, Orion Diagnostics). Serum
IL-6 and hepcidin were also detected. Serum IL-6 levels
were determined by standard ELISA Quantitative kits (R&D
Systems, Wiesbaden, Germany) at Department of Public Health
and Infectious Diseases, Sapienza University of Rome, Italy,
on the samples collected before and after treatment. Serum
hepcidin was detected according to competitive enzyme-linked
immunosorbent assay (Intrinsic Life Sciences, La Jolla, CA) at
Department of Public Health and Infectious Diseases, Sapienza
University of Rome, Italy.
The diagnosis of HT was performed at Institute Regina Elena,
Department of Medical Pathology, Rome, Italy according to
Jackson et al. (41). In particular, pregnant women with a history
of adverse outcomes including recurrent miscarriages, preterm
birth, intrauterine growth restriction, were screened for the
following HT markers before the enrolment: protein C, protein
S, activated protein C resistance, antithrombin deficiencies,
elevated coagulation factors, hyperhomocysteinemia, F5 R506Q
(factor V Leiden) and F2 G20210A (prothrombin G20210A)
mutations. When at least one of these HT markers was found,
pregnant women were considered affected by HT. All HT women
were further screened for hematological parameters as RBCs, Hb,
TSI, and sFtn as well as for serum IL-6 and serum hepcidin before
starting and after 30 days of the treatments.
Moreover, for all enrolled women, the values of hematocrit,
glycemia, uricemia, bilirubin, glutamic oxaloacetic transaminase,
glutamic pyruvic transaminase, cholesterol, triglyceride acid, and
electrolytes were evaluated at each visit (data not shown).
Clinical Examination
To evaluate the putative adverse effects of the treatments
in pregnant women, the main outcomes were based on the
estimation of maternal gastrointestinal discomfort, nausea,
vomiting, diarrhea, and constipation.
At each visit, fetal vital sign assessments were monitored
by ultrasonographic measurements of intrauterine growth
and through the amount of amniotic fluid, expressed
as amniotic fluid index (AFI), an index for the fetal
well-being (42). An AFI of ≤5 cm was considered
oligohydramnios, 5–8 cm borderline, and from 8 to 24 cm
normal (42).
At the delivery, new-born weight and the APGAR score
were also registered. The APGAR score is a practical method
to evaluate the physical condition of a new-born shortly after
delivery. The Apgar score comprises five components: (1) color,
(2) heart rate, (3) reflexes, (4) muscle tone, and (5) respiration,
each of which is given a score of 0, 1, or 2. An APGAR score
of 0–3 at 5–10min of age is predictive of high morbidity and
mortality, a score of 4–6 as moderately abnormal, while a value
of 9–10 indicates that the infant is in the best possible condition.
The adverse effects in women of child-bearing age were
evaluated by gastrointestinal discomfort, nausea, vomiting,
diarrhea and constipation.
Interventions
Pregnant and child-bearing age women affected by minor β-
thalassemia and HT suffering from anemia and AI, respectively,
were assigned to different Arms on the basis of a personal
preference. As matter of fact, before starting the study patients
choose by themselves which treatment to adhere to.
Women included in Arm A, C, E, and G received the
treatment based on the oral administration of one capsule
containing 100mg of bLf plus excipients (Lattoglobina R©, Italy)
two times a day before meals, to avoid the protein degradation
due to the low pH of gastric juice during digestion (about
1.5). Conversely, at pH about 4, characteristic of gastric juice
before meals, 90% of the administered bLf arrives undigested
to the intestine (43). The total amount of elemental iron
supplied by Lattoglobina R© capsules corresponded to about 70–
84 µg/day, depending on the degree of iron saturation (20–
30%). Women included in Arm B, D, F, and H received the
standard treatment based on the oral administration of a tablet
containing 329.7mg of ferrous sulfate (Ferro-Grad R©, Abbot
Laboratories, USA) once a day during meal, in order to avoid
a possible gastric intolerance of the drug, according to the
Italian Standard of Care. The total amount of elemental iron
supplied by Ferro-Grad R© tablets corresponded to about 105
mg/day.
All pregnant women affected by different pathologies,
previously described, received oral administration of one capsule
containing 100mg of bLf plus excipients (Lattoglobina R©,
Italy) twice a day before meals, while HT women with twin
pregnancies three times a day, more efficient in increasing
hematological parameters than the administration of bLf twice
a day.
Further Laboratory Analysis
The purity of the encapsulated bLf (Molecular Weight of about
80 kDa) was checked by SDS-PAGE and silver nitrate staining,
while its concentration was assessed by UV spectroscopy on the
basis of an extinction coefficient of 15.1 (280 nm, 1% solution).
The bLf iron saturation was about 20–30% as detected by
optical spectroscopy at 468 nm on the basis of an extinction
coefficient of 0.54 (100% iron saturation, 1% solution). The
total amount of elemental iron supplied by Lattoglobina R©
capsules corresponded to about 70–84 µg/day, depending on
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FIGURE 1 | Flow diagrams of enrolled pregnant women suffering from minor β-thalassemia (A), pregnant women suffering from hereditary thrombophilia (B), women
of child-bearing age suffering from minor β-thalassemia (C), women of child-bearing age suffering from hereditary thrombophilia (D).
the degree of iron saturation (20–30%). LPS contamination of
bLf, estimated by Limulus Amebocyte assay (Pyrochrome kit,
PBI International), was equal to 0.7 ± 0.06 ng/mg of bLf (9,
43).
Statistical Analysis
Statistical analysis was carried out using the ANOVA test. P-
values has been obtained comparing before and after 30 days of
each treatment the number of RBCs, the concentration of Hb,
TSI, sFtn, IL-6 and hepcidin.
RESULTS
Demographics
A total of 20 minor β-thalassemic and 70 HT pregnant women
suffering from anemia and AI, respectively, was enrolled in
the interventional clinical trial within the first trimester of
pregnancy (Figures 1A,B). On the basis of their personal
preference, 12 and 8 minor β-thalassemic pregnant women
were included in Arm A (bLf intervention) and Arm B
(ferrous sulfate intervention), respectively (Figure 1A). Among
8 minor β-thalassemic pregnant women belonging to Arm B, 2
withdrew the study for adverse effects (diarrhea) (Figure 1A).
Regarding HT pregnant women, on the basis of their personal
preference, 40 were included in Arm C (bLf intervention)
and 30 in Arm D (ferrous sulfate intervention) (Figure 1B).
Among 30 HT pregnant women belonging to Arm D, 5
withdrew the study for adverse effects: 2 for gastrointestinal
discomfort and 3 for diarrhea (Figure 1B). Demographics and
hematological parameters of minor β-thalassemic and HT
pregnant women, who completed the study, are reported in
Table 1.
Moreover, 20 anemic pregnant women suffering from
other pathologies, including epilepsy (No 9), insulin
resistance diabetes type 2 (No 3), Crohn’s disease (No 3),
hypertension (No 2) and HT with twin pregnancies (No 3),
have been enrolled at different trimesters of pregnancy
and exclusively treated with bLf oral administration.
Demographics as well as Hb and TSI values are reported in
Table 2.
A total of 9 minor β-thalassemic and 79 HT women of child-
bearing age suffering from anemia and AI, respectively, was also
enrolled. On the basis of their personal preference, 9 minor β-
thalassemic women of child-bearing age were divided in Arm
E (No 5, bLf intervention) and Arm F (No 4, ferrous sulfate
intervention), respectively, and completed the study (Figure 1C).
Regarding HT women of child-bearing age, on the basis of
their personal preference, 41 were included in Arm G (bLf
intervention) and 38 in Arm H (ferrous sulfate intervention)
(Figure 1D). Among 38 HT women belonging to Arm H, 2
withdrew the study for nausea and vomiting and 4 for diarrhea
(Figure 1D).
Demographics and hematological parameters of enrolled
women of child-bearing age are summarized in Table 3.
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TABLE 1 | Demographics and baseline of hematological mean values ± SD of
minor β-thalassemic and HT pregnant women affected by anemia and AI,
respectively, enrolled between the 6th and 8th week of gestation.
Minor β-thalassemic
pregnant women
HT pregnant
women
No of pregnant women
completing the study
18 65
Age (year) 28 ± 3 34 ± 3
Red blood cells x103 4,470 ± 184 3,700 ± 145
Hemoglobin (g/dl) 7.7 ± 1.4 10.7 ± 0.6
Total serum iron (µg/dl) 50 ± 14 38 ± 13
Serum ferritin (ng/ml) 24 ± 4 14 ± 10
Serum IL-6 (pg/ml) 29 ± 9 87 ± 10
Hepcidin (ng/ml) <1.0 111 ± 26
TABLE 2 | Demographics and baseline of hemoglobin and total serum iron mean
values ± SD of pathological pregnancies affected by anemia enrolled at different
trimesters of gestation.
No of
women
Pathology Age
(year)
Week of
pregnancy
Hb
(g/dl)
TSI
(µg/dl)
9 Epilepsy 33 ± 4 17 ± 6 11.1 ± 0.6 42 ± 16
3 Insulin resistance
diabetes type 2
35 ± 4 28 ± 4 10.4 ± 0.3 33 ± 2
3 Crohn’s disease 31 ± 4 29 ± 4 9.4 ± 1.0 57 ± 7
2 Hypertension 34 ± 4 24 ± 2 10.7 ± 0.3 35 ± 5
3 HT (twin) 33 ± 2 25 ± 8 10.5 ± 0.5 47 ± 14
Hb, hemoglobin; TSI, total serum iron.
Efficacy of Bovine Lactoferrin vs. Ferrous
Sulfate Treatment in Pregnancy Against
Anemia and AI
In pregnant women suffering from minor β-thalassemia and
HT, the RBCs, Hb, TSI, sFtn, serum IL-6, and hepcidin were
assessed before and every 30 days of treatments until delivery.
The results obtained after the first 30 days of both interventions
and at delivery, independently from the week of the gestation,
are presented in the Tables 4, 5 for minor β-thalassemic and in
Tables 6, 7 for HT pregnant women, respectively.
As shown in Table 4, minor β-thalassemic pregnant women
treated for 30 days with bLf (Arm A) showed a significant
increase of Hb (from 7.8 ± 1.3 to 11.7 ± 0.8 g/dl) as well as a
signficant decrease of IL-6 (from 25± 8 to 6± 3 pg/ml). Of note,
a remarkable increase of TSI (from 54 ± 17 to 80 ± 9 µg/dl)
was also observed. Conversely, minor β-thalassemic pregnant
women treated for 30 days with ferrous sulfate (Arm B) showed
a significant increase only for Hb (from 7.6 ± 1.6 to 10.2 ± 0.9
g/dl) while RBCs, TSI, sFtn and IL-6 levels remained unchanged
(Table 4). Regarding serum hepcidin concentration, it was not
detectable either before or after both treatments. At delivery,
in the bLf-treated minor β-thalassemic women, in addition to
a significant decrease of IL-6 (from 25 ± 8 to 5 ± 4 pg/ml), a
significant increase of Hb (from 7.8 ± 1.3 to 11.9 ± 0.7 g/dl)
TABLE 3 | Demographics and baseline hematological mean values ± SD of minor
β-thalassemic and HT women of child-bearing age affected by anemia and AI,
respectively.
Minor β-thalassemic
women
HT
women
No of women completing
the study
9 73
Age (year) 32 ± 2 31 ± 3
Red blood cells × 103 4,287 ± 497 3,876 ± 247
Hemoglobin (g/dl) 10.6 ± 1.3 10.9 ± 0.8
Total serum iron (µg/dl) 41 ± 11 38 ± 11
Serum ferritin (ng/ml) 15 ± 5 10 ± 4
Serum IL-6 (pg/ml) 25 ± 13 43 ± 11
Hepcidin (ng/ml) <1.0 102 ± 9
as well as a remarkable increase of both TSI (from 54 ± 17
to 87 ± 16 µg/dl) and sFtn (from 23 ± 5 to 34 ± 6 ng/ml)
were observed (Table 5). Conversely, in ferrous sulfate-treated
minor β-thalassemic women, excepted for Hb concentration,
no increase of other hematological parameters was detected
(Table 5).
As shown in Table 6, HT pregnant women treated for 30 days
with bLf (Arm C) showed a significant increase of RBCs (from
3,750± 127× 103 to 4,354± 198× 103), Hb (from 10.6± 0.4 to
12.2 ± 0.4 g/dl), TSI (from 36 ± 11 to 63 ± 9 µg/dl) and a slight
increase of sFtn (from 11 ± 6 to 18 ± 2 ng/ml). These women
presented high basal levels of IL-6 (89 ± 8 pg/ml) and hepcidin
(115 ± 23 ng/ml) which were both significantly reduced (58 ±
6 pg/ml and 65 ± 10 ng/ml, respectively) already after 30 days
of bLf treatment. Conversely, HT pregnant women treated for 30
days with ferrous sulfate (ArmD) showed a trend (p> 0.005), yet
not significant, toward an increase of RBCs (from 3,650± 163×
103 to 3,960 ± 230 × 103) and Hb (from 10.8 ± 0.8 to 11.3 ±
1.1 g/dl). Of note, both IL-6 and hepcidin levels do not show any
change after the treatment.
At delivery, the bLf-treated HT women showed significant
increases in all hematological values, such as RBCs (from 3,750
± 127 × 103 to 4,482 ± 147 × 103), Hb (from 10.6 ± 0.4 to
12.7 ± 0.5 g/dl), TSI (from 36 ± 11 to 85 ± 10 µg/dl) and sFtn
(from 11 ± 6 to 31 ± 3 ng/ml), as well as a significant decrease
in both IL-6 and hepcidin levels (from 89 ± 8 to 50 ± 5 pg/ml
and from 115 ± 23 to 65 ± 10 ng/ml, respectively). Conversely,
HT women treated with ferrous sulfate management, showed no
significant difference in any parameter evaluated compared to
those obtained before the treatment (Table 7).
Fetus and New-Born Outcomes
The adverse effects of bLf and ferrous sulfate treatments on
fetuses were monitored through ultrasonographic measurements
of intrauterine growth and by the detection of amniotic fluid
amount, expressed as AFI (39). No growth restriction was
observed for any fetus. The AFI ranged from 13.4 ± 1.6 mean
values at 34 weeks to 10.5 ± 2.3 mean values at 40 weeks. It is
interesting to note that all the values were within 8 to 24 cm range,
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TABLE 4 | Hematological parameters, serum IL-6 and hepcidin mean values ± SD of anemic minor β-thalassemic pregnant women treated with bovine lactoferrin (Arm A)
or ferrous sulfate (Arm B), before and after 30 days of treatment.
Minor β-thalassemic pregnant women
Arm A Arm B
No of pregnant women completing the study 12 6
Treatment Bovine lactoferrin Ferrous sulfate
Before After 30 days Before After 30 days
Red blood cells × 103 4,487 ± 167 4,460 ± 121 4,453 ± 201 4,130 ± 123
Hemoglobin (g/dl) 7.8 ± 1.3 11.7 ± 0.8* 7.6 ± 1.6 10.2 ± 0.9*
Total serum iron (µg/dl) 54 ± 17 80 ± 9 46 ± 11 50 ± 12
Serum ferritin (ng/ml) 23 ± 5 28 ± 3 25 ± 3 24 ± 4
Serum IL-6 (pg/ml) 25 ± 8 6 ± 3* 33 ± 10 36 ± 8
Hepcidin (ng/ml) <1.0 <1.0 <1.0 <1.0
*Significantly different from before treatment (p < 0.001).
TABLE 5 | Hematological parameters, serum IL-6 and hepcidin mean values ± SD of anemic minor β-thalassemic pregnant women treated with bovine lactoferrin (Arm A)
or ferrous sulfate (Arm B), before the treatment and at delivery.
Minor β-thalassemic pregnant women
Arm A Arm B
No of pregnant women completing the study 12 6
Treatment Bovine lactoferrin Ferrous sulfate
Before At delivery Before At delivery
Red blood cells × 103 4,487 ± 167 4,610 ± 196 4,453 ± 201 4,284 ± 183
Hemoglobin (g/dl) 7.8 ± 1.3 11.9 ± 0.7* 7.6 ± 1.6 10.8 ± 0.6*
Total serum iron (µg/dl) 54 ± 17 87 ± 16 46 ± 11 55 ± 17
Serum ferritin (ng/ml) 23 ± 5 34 ± 6 25 ± 3 21 ± 7
Serum IL-6 (pg/ml) 25 ± 8 5 ± 4* 33 ± 10 34 ± 10
Hepcidin (ng/ml) <1.0 <1.0 <1.0 <1.0
*Significantly different from before treatment (p < 0.001).
which is accepted and established as normal range for AFI values
(42).
The adverse effects on new-born were checked by new-born
weight and APGAR score values. For both treatments, the new-
born weight ranged among mean values corresponding to 2,950
± 427 g for female and 3,478± 256 g for male. The APGAR score
corresponded to range values of 8–10 for both sex, indicating
new-born well-being.
Efficacy of Bovine Lactoferrin Treatment in
Pregnant Women Affected by Various
Pathologies Against Anemia
Table 8 presents 20 anemic pregnant women affected by different
pathologies including also 3 HT twin pregnancies. The treatment
based on bLf oral administration appeared reasonably efficient in
treating anemia by increasing both Hb and TSI concentrations.
Even if the other hematological parameters were not evaluated,
bLf is efficient in increasing these two parameters related to
anemia. Interestingly, 9 patients suffering from epilepsy showed
an increase of about 2- or 3-fold of TSI concentration and
more than 1 g/dl of Hb. In 3 pregnant women affected by
insulin resistance diabetes type 2, bLf intervention showed an
increase of both Hb and TSI similarly to that observed in 3
pregnancies affected by Crohn’s disease. The efficacy of bLf
oral administration has been also observed in 2 women with
hypertension during the gestation. Of note, a great efficacy has
been also observed in 3 HT twin pregnancies treated with 100mg
bLf three times a day before meals (instead of two times a day
usually applied).
Efficacy of Bovine Lactoferrin vs. Ferrous
Sulfate Treatment in Women of
Child-Bearing Age Against Anemia and AI
Minor β-thalassemic women of child-bearing age treated for
30 days with bLf oral administration (Arm E) showed a
remarkable, yet not significant, increase of both RBCs (from
4,280 ± 484 × 103 to 4,990 ± 323 × 103) and TSI (from
43 ± 11 to 84 ± 11 µg/dl). Moreover, slight increases
in Hb (10.2 ± 0.8 to 11.3 ± 0.9 g/dl) and sFtn (from
18 ± 3 to 26 ± 5 ng/ml) levels as well as a decrease of
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TABLE 6 | Hematological parameters, serum IL-6 and hepcidin mean values ± SD of HT pregnant women, suffering from AI, treated with bovine lactoferrin (Arm C) or
with ferrous sulfate (Arm D), before and after 30 days of treatment.
HT pregnant women
Arm C Arm D
No of pregnant women completing the study 40 25
Treatment Bovine lactoferrin Ferrous sulfate
Before After 30 days Before After 30 days
Red blood cells × 103 3,750 ± 127 4,354 ± 198* 3,650 ± 163 3,960 ± 230
Hemoglobin (g/dl) 10.6 ± 0.4 12.2 ± 0.4* 10.8 ± 0.8 11.3 ± 1.1
Total serum iron (µg/dl) 36 ± 11 63 ± 9* 40 ± 15 40 ± 6
Serum ferritin (ng/ml) 11 ± 6 18 ± 2 17 ± 14 14 ± 9
Serum IL-6 (pg/ml) 89 ± 8 58 ± 6* 85 ± 12 108 ± 7
Hepcidin (ng/ml) 115 ± 23 65 ± 10* 107 ± 29 112 ± 32
*Significantly different from before treatment (p < 0.001).
TABLE 7 | Hematological parameters, serum IL-6 and hepcidin mean values ± SD of HT pregnant women, suffering from AI, treated with bovine lactoferrin (Arm C) or
with ferrous sulfate (Arm D), before the treatment and at delivery.
HT pregnant women
Arm C Arm D
No of pregnant women completing the study 40 25
Treatment Bovine lactoferrin Ferrous sulfate
Before At delivery Before At delivery
Red blood cells × 103 3,750 ± 127 4,482 ± 147* 3,650 ± 163 4,029 ± 287
Hemoglobin (g/dl) 10.6 ± 0.4 12.7 ± 0.5* 10.8 ± 0.8 11.2 ± 0.9
Total serum iron (µg/dl) 36 ± 11 85 ± 10* 40 ± 15 38 ± 11
Serum ferritin (ng/ml) 11 ± 6 31 ± 3* 17 ± 14 12 ± 10
Serum IL-6 (pg/ml) 89 ± 8 50 ± 5* 85 ± 12 113 ± 15
Hepcidin (ng/ml) 115 ± 23 54 ± 13* 107 ± 29 116 ± 26
* Significantly different from before treatment (p < 0.001).
serum IL-6 (from 24 ± 12 to 13 ± 8 pg/ml) concentration
have been observed (Table 9). Conversely, no parameter was
modified after ferrous sulfate treatment (Arm F). In addition,
as observed in minor β-thalassemic pregnancies, hepcidin
concentrations in minor β-thalassemic women of child-bearing
age was not detectable (<1 ng/ml). Both bLf and ferrous sulfate
interventions did not exert any effect on hepcidin synthesis
(Table 9).
Regarding HT women of child-bearing age, bLf treatment
(Arm G) significantly increased the number of RBCs (from 3,664
± 205 × 103 to 4,280 ± 187 × 103) and the concentration of
Hb (10.4 ± 0.8 to 12.5 ± 0.6 g/dl), TSI (from 36 ± 10 to 90 ±
12 µg/dl) and sFtn (from 9 ± 3 to 22 ± 6 ng/ml). Furthermore,
this treatment also significantly decreased serum IL-6 and
hepcidin synthesis (Table 10), similarly to that observed in HT
pregnancies.
Conversely, ferrous sulfate treatment in HT women of
child-bearing age (Arm H) showed only a slight, yet not
significant, increase for Hb and TSI. Of note, both IL-6 and
hepcidin levels do not show any change after the treatment
(Table 10).
DISCUSSION
Recently, Lf, a multifunctional glycoprotein, endowed with
potent immune-modulatory properties, is emerging as an
important component of iron and inflammatory homeostasis
machinery (4, 23).
In 2006, by designing our first clinical trial on the effect of
30 days of bLf oral administration (100mg two times a day
before meals) compared with oral administration of ferrous
sulfate (329.7mg once a day during the meal) in anemic
pregnant women, surprising results were obtained (36). Pregnant
women receiving iron saturated bLf (20–30%) two times a day,
absorbed 70–84 µg/day of elemental iron, respectively, through
enterocytes. Although the concentration of iron supplemented
by bLf is very far from that required daily (1–2mg), a significant
increase of the concentration of Hb and TSI was detected 30 days
after treatment. Later on, in our subsequent clinical trials carried
out on pregnant women suffering from anemia and AI, bLf
treatment induced, in addition to Hb and TSI levels, a significant
improvement of the number of RBCs and sFtn concentrations.
Interestingly, a significant decrease of serum levels of IL-6,
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TABLE 8 | Mean values ± SD of hemoglobin and total serum iron of anemic pregnant women suffering from different pathologies treated for 30 days with bovine
lactoferrin.
No of women Pathology Age (year) Week of pregnancy Hb (g/dl) TSI (µg/dl)
Before After 30 days Before After 30 days
9 Epilepsy 33 ± 4 17 ± 6 11.1 ± 0.6 12.7 ± 0.4 42 ± 16 111 ± 24
3 Insulin resistance diabetes type 2 35 ± 4 28 ± 4 10.4 ± 0.3 11.4 ± 0.3 33 ± 2 56 ± 11
3 Crohn’s disease 31 ± 4 29 ± 4 9.4 ± 1.0 10.6 ± 0.5 57 ± 7 67 ± 8
2 Hypertension 34 ± 4 24 ± 2 10.7 ± 0.3 11.4 ± 0.1 35 ± 5 70 ± 14
3 HT twin 33 ± 2 25 ± 8 10.5 ± 0.5 11.6 ± 0.3 47 ± 14 99 ± 13
Hb, hemoglobin; TSI, total serum iron.
TABLE 9 | Hematological parameters, serum IL-6 and hepcidin mean values ± SD of anemic minor β-thalassemic women of child-bearing age treated with bovine
lactoferrin (Arm E) or with ferrous sulfate (Arm F), before and after 30 days of treatment.
Minor β-thalassemic women
Arm E Arm F
No of women completing the study 5 4
Treatment Bovine lactoferrin Ferrous sulfate
Before After 30 days Before After 30 days
Red blood cells × 103 4,280 ± 484 4,990 ± 323 4,294 ± 510 4,460 ± 315
Hemoglobin (g/dl) 10.2 ± 0.8 11.3 ± 0.9 11.0 ± 1.8 12.2 ± 1.3
Total serum iron (µg/dl) 43 ± 11 84 ± 11 39 ± 11 40 ± 15
Serum ferritin (ng/ml) 18 ± 3 26 ± 5 12 ± 7 15 ± 5
Serum IL-6 (pg/ml) 24 ± 12 13 ± 8 26 ± 14 32 ± 11
Hepcidin (ng/ml) <1.0 <1.0 <1.0 <1.0
considered a key pro-inflammatory cytokine in iron homeostasis,
was observed (4, 29, 37, 38). Differently from bLf, ferrous sulfate
was ineffective in treating anemia and AI even if iron supply
was a 1,000-fold higher than that furnished by bLf (about 100
mg/day vs. about 80 µg/day). Moreover, ferrous sulfate does
not decrease the levels of serum IL-6 (4, 29, 36–38). Therefore,
even if the mechanism by which bLf exerts its anti-inflammatory
activity is still under debate, there are strong evidences that bLf
efficacy in treating anemia and AI is not linked to a direct iron
supplementation, but to a more complex mechanism involving
this protein in decreasing IL-6 andmodulating hepcidin and Fpn,
the most important iron homeostasis actors, both regulated by
IL-6 (23, 44).
In this respect, our group has recently demonstrated that
bLf is able to revert the iron disorders in human inflamed-
macrophages. In particular, bLf, by exerting its anti-inflammatory
activity vs. IL-6 synthesis, determines the up-regulation of Fpn
expression, thus leading to an efficient recovery of iron efflux
from cells to blood (8, 9).
The bLf anti-inflammatory activity has been explained by the
discovery of its nuclear localization thus suggesting that this
molecule may be involved in the transcriptional regulation of
some genes of host inflammatory response (4, 45, 46). Lf is,
therefore, a key element not only in the host defense system
(47–49) but also a pivotal glycoprotein able to treat anemia
through the inhibition of the inflammatory response, especially
in pregnant women affected by HT (29).
Here, we present novel and promising results on the efficacy
and safety of bLf treatment in curing anemia and AI in minor
β-thalassemic and HT pregnant and non-pregnant women,
respectively, as well as anemia in pregnant women suffering from
various pathologies.
For the first time, the serum hepcidin has been detected in
minor β-thalassemic andHT pregnant and non-pregnant women
and correlated with all the other clinical parameters evaluated
before and after bLf or ferrous sulfate management.
Furthermore, we confirm the results obtained in our previous
clinical trials on HT pregnancies (29) through the enrolment
of additional 70 HT pregnant women and 79 HT women of
child-bearing age.
Overall, both HT pregnant and non-pregnant women, after
30 days of bLf treatment, show a significant increase of RBCs,
Hb, TSI and sFtn. Of note, bLf treatment also significantly
reduces IL-6 and hepcidin levels compared to the high basal
concentrations (Table 6 Arm C and Table 10 Arm G). The effect
of bLf treatment, leading to the down-regulation of hepcidin
synthesis, should be considered as a signal of a regulatory
mechanism exerted by bLf to avoid the pathological intracellular
iron overload, thus restoring the physiological iron export to
blood through Fpn up-regulation. In fact, the persistence of
high levels of IL-6 and hepcidin would inhibit the iron export
through the down-regulation and degradation of Fpn, causing
an unsafe intracellular iron overload, specially in those cells
involved in iron absorption and recycle, such as enterocytes
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TABLE 10 | Hematological parameters, serum IL-6 and hepcidin mean values ± SD of HT women of child-bearing age, suffering from AI treated with bovine lactoferrin
(Arm G) or with ferrous sulfate (Arm H), before and after 30 days of treatment.
HT women
Arm G Arm H
No of women completing the study 41 32
Treatment Bovine lactoferrin Ferrous sulfate
Before After 30 days Before After 30 days
Red blood cells × 103 3,664 ± 205 4,280 ± 187* 4,088 ± 289 3,989 ± 265
Hemoglobin (g/dl) 10.4 ± 0.8 12.5 ± 0.6* 11.4 ± 0.8 11.8 ± 1.0
Total serum iron (µg/dl) 36 ± 10 90 ± 12* 40 ± 12 45 ± 15
Serum ferritin (ng/ml) 9 ± 3 22 ± 6* 11 ± 5 14 ± 6
Serum IL-6 (pg/ml) 45 ± 9 9 ± 8* 41 ± 13 49 ± 8
Hepcidin (ng/ml) 100 ± 8 60 ± 18* 104 ± 10 100 ± 15
*Significantly different from before treatment (p < 0.001).
and macrophages, respectively. As matter of fact, inflammation-
mediated iron retention in macrophages determines the most
pivotal cause of AI establishment and maintenance. Indeed,
upon inflammatory stimulation, macrophages polarize in a sub-
population, namely M1, characterized by production of pro-
inflammatory cytokines, such as IL-6, the down-regulation of
Fpn and up-regulation of cytosolic Ftn, leading to the block
of iron recycling to blood from senescent erythrocytes, the
major iron source for the body (50, 51). The current finding
that bLf, through its anti-inflammatory activity, is able to
revert this unsafe condition restoring the physiological iron
export from macrophages to blood can be considered an
actual molecular mechanism to explain the bLf efficacy, iron
independent, in treating AI in HT pregnant and non-pregnant
women.
Conversely, ferrous sulfate treatment in HT pregnant and
non-pregnant women shows a trend toward an increase in only
RBCs and Hb. Moreover, this management fails in decreasing
both IL-6 and hepcidin levels (Table 6 Arm D and Table 10 Arm
H). The failure of ferrous sulfate treatment could be explained by
its inability to modulate hepcidin or Fpn expression in a direct
way (never demonstrated) or indirectly through the inhibition of
IL-6 synthesis (never demonstrated).
The efficacy of bLf oral administration in treating anemia
was also tested on pregnant women suffering from various
pathologies. In these pregnant women bLf management appears
effective (Table 8). Of note, regarding pregnant women affected
by epilepsy, bLf treatment greatly increases TSI concentration
(about 2- or 3-fold) and Hb (about 1 g/dl). The encouraging
results were also obtained on HT twin pregnancies where the
management has required an additional oral administration of
bLf (100mg three times a day).
In this interventional study, the efficacy of bLf oral
administration has been also demonstrated in anemic pregnant
and non-pregnant women affected by minor β-thalassemia,
an inherited autosomal recessive Hb disorder characterized by
reduced synthesis of the β-chain of Hb (24).
Even if the number of enrolled minor β-thalassemic women
is low and does not allow to obtain conclusive and convincing
results, bLf treatment demonstrates a simultaneous decrease
in IL-6 and an increase in TSI both in pregnant and non-
pregnant women even if at different extent (Table 4 Arm A
and Table 9 Arm E). Remarkably, in these subjects hepcidin
is not detectable both before and after bLf management. This
observation supports the hypothesis that bLf, independently
from hepcidin but dependently from IL-6 down-regulation, may
act as a positive regulator of Fpn, thus increasing iron efflux
to blood. This potential mechanism is indeed supported by the
increase of TSI values in all minor β-thalassemic women already
after 30 days of bLf treatment (Table 4 Arm A and Table 9 Arm
E).
Similar to bLf, ferrous sulfate treatment in minor β-
thalassemic pregnant and non-pregnant women leads to an
increase of Hb concentration while, conversely to bLf, it does
not influence IL-6 synthesis (Table 4 Arm B and Table 9 Arm F).
Regarding serum hepcidin concentration, it was not detectable
before and after ferrous sulfate intervention (Table 4 Arm B and
Table 9 Arm F). Taken together all the results, alternatively to
the hepcidin agonists or antagonists as therapeutic tools (20),
bLf oral administration can be considered as a first promising
compound in treating anemia through the decrease of both IL-6
and hepcidin thus restoring Fpn-mediated iron export from cells
to blood in an hepcidin dependent or independent way.
Even if the number of patients is low and further investigations
are required, these results highlight and support the importance
of bLf oral administration in the treatment of the iron and
inflammatory homeostasis disorders.
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